Raloxifene Hydrochloride Tablet, Film Coated
Product Images NDC 0093-7290

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Raloxifene Hydrochloride (NDC 0093-7290). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1

Chemical structure of Raloxifene Hydrochloride, showing its molecular framework including phenol, thiochromene, piperidine, and ether functional groups.*

FDA Label Image

Image 2

Two line graphs depicting total hip mean percentage change from baseline over 24 months. The first compares Raloxifene Hydrochloride and placebo subjects from Studies NA and EU, showing percentage change on the vertical axis and months after randomization on the horizontal axis. The second graph compares conjugated estrogens (CE), Raloxifene Hydrochloride, and placebo in hysterectomized women from Study INT, with the same axes and time frame.*

FDA Label Image

Image 3

Raloxifene Hydrochloride Tablets, USP 60 mg film-coated oral tablets. The label shows 30 tablets in the package, labeled by Teva Pharmaceuticals USA, Inc. It includes a barcode, NDC number 0093-7290-56, and instructions for pharmacists to dispense the Medication Guide to each patient. The label revision date is 8/2021.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.